143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma

Background

The prognosis of patients with metastatic renal cell carcinoma (mRCC) has improved markedly with the introduction of molecular-targeted agents and immune checkpoint inhibitors. However, there are few reports on the outcome of systemic therapy for hemodialysis patients with mRCC. The purpose of this study is to evaluate the outcome of the systemic therapy for hemodialysis patients with mRCC.

Methods

We retrospectively studied 253 patients with mRCC (17 hemodialysis patients and 236 non-dialysis patients) treated with systemic therapy at Keio University Hospital in Japan. A progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier method.

Results

The pathological diagnosis of the clear cell carcinoma was 52.9% in hemodialysis patients and 82.6% in non-dialysis patients (p=0.007). Hemodialysis patients (10 intermediate risk; 7 poor risk) received first line therapy; 4 received cytokine therapy, 11 received tyrosine kinase inhibitor, 1 received mTOR inhibitor, and 1 received immune checkpoint inhibitor. A median PFS was 6.9 months for hemodialysis patients and 17.0 months for non-dialysis patients (p<0.001), and median OS was 21.2 months for hemodialysis patients and 49.4 months for non-dialysis patients (p<0.001), respectively.

Conclusions

PFS and OS were significantly shorter in hemodialysis patients with mRCC compared to non-dialysis patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.